ACM
KPTI icon

ADAR1 Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

ADAR1 Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-136,736
Closed -$762K – 314
2026
Q1 		$762K Buy
136,736
+86,736
+173% +$661K 0.04% 182
2025
Q4 		$368K Buy
50,000
+25,000
+100% +$153K 0.03% 201
2025
Q3 		$164K Buy
+25,000
New +$135K 0.02% 186
2025
Q1 		– Sell
-1,333
Closed -$13.5K – 234
2024
Q4 		$13.5K Buy
+1,333
New +$16.1K ﹤0.01% 203
2024
Q2 		– Sell
-99
Closed -$2.23K – 297
2024
Q1 		$2.23K Buy
+99
New +$1.74K ﹤0.01% 248

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ADAR1 Capital Management's KPTI Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 136,736 shares — an estimated $762K sold.

ADAR1 Capital Management first reported a position in KPTI in Q1 2024 and held it in 5 quarters. The position peaked at $762K in Q1 2026. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 136,736 Karyopharm Therapeutics shares in Q2 2026, an estimated $762K.
  • ADAR1 Capital Management first reported a position in Karyopharm Therapeutics in Q1 2024 and held it in 5 quarters.
  • ADAR1 Capital Management's Karyopharm Therapeutics position peaked at $762K in Q1 2026.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.